VP, Regulatory & Medical Affairs
Catherine identifies opportunities for clinical research partnerships that fulfill Tilray's goal of advancing knowledge of cannabinoid science by partnering with physicians and medical institutions to generate data that will inform best treatment practices. This data includes information on appropriate dosages, potential adverse effects, and other considerations important to patient populations given the particular symptoms and natural history of each disease.
Director of Research Investment for The Epilepsy Foundation
Prior to joining Privateer Holdings, Catherine led a venture philanthropic fund addressing the lack of adequate drugs and devices to treat pediatric epilepsy. Before that, she served as a post-doctoral fellow at the University of California, San Francisco where she established GW Pharmaceutical's Expanded Access Investigational New Drug Application (IND) for Epidiolex for the treatment of children with severe medically refractory epilepsy. Previously, she also served as a post-doctoral fellow at Stanford University, where she conducted the first published account of the parental use of cannabis to treat severe pediatric epilepsy.
University of Colorado, Boulder: BA, Psychology
Oregon Health and Science University School of Medicine: PhD, Cell Biology, Neuroscience